Freyer, Gilles, 1967-....
Gilles Freyer French professor, oncologist and medical professional
Freyer, Gilles
VIAF ID: 17442808 (Personal)
Permalink: http://viaf.org/viaf/17442808
Preferred Forms
-
- 100 1 _ ‡a Freyer, Gilles
-
- 100 1 _ ‡a Freyer, Gilles
-
-
- 100 1 _ ‡a Freyer, Gilles, ‡d 1967-....
- 100 0 _ ‡a Gilles Freyer ‡c French professor, oncologist and medical professional
Works
Title | Sources |
---|---|
Adaptation of dosing regimen of chemotherapies based on pharmacodynamic models | |
Analyse dynamique de la cinétique de décroissance des marqueurs tumoraux sériques en cours de traitement au moyen de la modélisation et de la cinétique de population. | |
Apport de la pharmacocinétique de population à l'individualisation posologique des agents cytotoxiques : l'exemple du carcinome bronchique indifférencié à petites cellules traité par une polychimiothérapie de type A.V.I. (adriamycine - étoposide - ifosfamide) | |
après-cancer | |
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors | |
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial | |
Biology of cancer and aging: a complex association with cellular senescence. | |
Biomarqueurs circulants dans le cancer de la prostate métastatique résistant à la castration | |
Cancérologie oncohématologie | |
Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. | |
Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over Time | |
LA CHIMIOTHERAPIE DES CANCERS DES SUJETS AGES A-T-ELLE UNE SPECIFICITE ? | |
[CHIP and ovarian cancer] | |
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial | |
Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials | |
Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice | |
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment | |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients | |
Dénoncer et bannir | |
Dynamic analysis of serum tumor marker decline during anti-cancer treatment using population kinetic modeling approach | |
EPICC study: evaluation of pharmaceutical intervention in cancer care | |
Ethics and the risk of institutionalisation : incidence is the event possible at the heart of the hospital curing machine?. | |
Étude par la modélisation pharmacologique de la non-observance aux chimiothérapies anticancéreuses orales | |
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib | |
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease | |
Faire face au cancer : l'espoir au quotidien | |
Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS). | |
Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey | |
Guide pratique de la décision médicale : l'éthique en clinique | |
Hépato-gastroentérologie | |
Homeopathic medicine in cancer care. | |
Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases | |
Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work. | |
Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients | |
Improving cancer patient care with combined medication error reviews and morbidity and mortality conferences | |
Inclusion of elderly patients in oncology clinical trials. | |
Infection et thrombose sur cathéter veineux central chez le patient cancéreux : évaluation des pratiques sur une population hospitalière de 150 patients | |
Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model | |
[Is geriatric assessment adapted to radiotherapy?] | |
Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model | |
Manuel de prise en charge du cancer colorectal chez le sujet âgé | |
Mechanistic model-based drug development in the management of anticancer drugs resistance | |
Médecine et pharmacie : les clés pour réussir | |
[Metastatic prostate cancer treatment in the elderly] | |
Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings | |
Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial | |
[Neurosarcoma associated with neurofibromatosis 1. Apropos of a case and review of the literature] | |
La non-adhésion aux traitements oraux dans les situations adjuvantes et métastatiques des cancers | |
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial | |
obscurantisme progressiste | |
Open-label uncontrolled pilot study to evaluate complementary therapy with Ruta graveolens 9c in patients with advanced cancer. | |
Optimal management of breast cancer in the elderly patient: current perspectives | |
Oral vinorelbine: feasibility and safety profile. | |
Pancreatic Neuroendocrine Carcinoma Metastatic to the Breast as Part of the Multiple Endocrine Neoplasia Type 1 Syndrome | |
PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes. | |
[Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment] | |
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours | |
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. | |
Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients. | |
[Primary peritoneal tumors: report on a series of eight cases and review of the literature] | |
Prise en compte de la dépression en oncologie : les coulisses de la recherche | |
Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trials | |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups | |
Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy | |
Psychosocial impact of genetic testing in familial medullary-thyroid carcinoma: a multicentric pilot-evaluation. | |
Quality of life in patients at risk of medullary thyroid carcinoma and followed by a comprehensive medical network: trends for future evaluations | |
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. | |
Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study | |
SIMMEON-Prep study: SIMulation of Medication Errors in ONcology: prevention of antineoplastic preparation errors | |
Study of the impact of non-compliance to an oral anticancer chemotherapy by modling and simulation. | |
Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy | |
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study | |
Thérapies ciblées dans la prise en charge de la patiente âgée atteinte d'un cancer du sein : hormonothérapie, anti-HER2 et anti-angiogéniques | |
Traitement des rechutes tardives du cancer de l’ovaire. | |
Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate |